| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
153,880,000 |
| Market
Cap: |
35.48(B) |
| Last
Volume: |
985,059 |
Avg
Vol: |
1,343,380 |
| 52
Week Range: |
$190.52 - $313.41 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 6.9 |
| Insider 3/6 Months : 7.5 |
|
| Guru Rank Number : 1040 |
| Guru Rank Value : -1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
455 |
455 |
455 |
| Total Buy Value |
$0 |
$101,256 |
$101,256 |
$101,256 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
355 |
1,626 |
2,138 |
11,088 |
| Total Sell Value |
$77,779 |
$385,230 |
$524,266 |
$3,190,794 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
6 |
8 |
12 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Leaming Nancy |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,060 |
8,984 |
|
- |
|
| Denner Alexander J |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,060 |
8,950 |
|
- |
|
| Schenk Lynn |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,060 |
5,950 |
|
- |
|
| Sherwin Stephen A |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,060 |
5,905 |
|
- |
|
| Papadopoulos Stelios |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,590 |
18,170 |
|
- |
|
| Pangia Robert W |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,060 |
16,628 |
|
- |
|
| Dorsa Caroline |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,060 |
17,093 |
|
- |
|
| Koppel Adam |
EVP, Strategy and Bus. Dev. |
• • – |
2016-06-06 |
4 |
AS |
$290.00 |
$160,950 |
D/D |
(555) |
2,402 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-06-03 |
4 |
AS |
$290.00 |
$244,180 |
D/D |
(842) |
54,936 |
|
- |
|
| Koppel Adam |
EVP, Strategy and Bus. Dev. |
• – – |
2016-06-02 |
4 |
D |
$289.73 |
$154,716 |
D/D |
(534) |
2,957 |
|
- |
|
| Koppel Adam |
EVP, Strategy and Bus. Dev. |
• – – |
2016-06-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,643 |
3,491 |
|
- |
|
| Ehlers Michael D |
EVP, Research and Development |
• • – |
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,034 |
3,034 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-06-01 |
4 |
AS |
$287.97 |
$140,241 |
D/D |
(487) |
55,778 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-05-31 |
4 |
AS |
$290.00 |
$976,720 |
D/D |
(3,368) |
56,265 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-05-25 |
4 |
AS |
$280.00 |
$43,960 |
D/D |
(157) |
59,633 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-05-02 |
4 |
AS |
$274.74 |
$133,798 |
D/D |
(487) |
59,790 |
|
- |
|
| Covino Gregory F |
VP, Chief Accounting Officer |
• • – |
2016-05-01 |
4 |
D |
$274.99 |
$31,074 |
D/D |
(113) |
3,007 |
|
- |
|
| Covino Gregory F |
VP, Chief Accounting Officer |
• • – |
2016-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
348 |
3,120 |
|
- |
|
| Koppel Adam |
EVP, Strategy and Bus. Dev. |
• • – |
2016-04-06 |
4 |
AS |
$275.00 |
$28,050 |
D/D |
(102) |
1,848 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-04-06 |
4 |
AS |
$280.00 |
$43,960 |
D/D |
(157) |
60,277 |
|
- |
|
| Artavanis-Tsakonas Spyridon |
EVP, Chief Scientific Officer |
• • – |
2016-04-02 |
4 |
D |
$260.54 |
$119,588 |
D/D |
(459) |
3,150 |
|
- |
|
| Artavanis-Tsakonas Spyridon |
EVP, Chief Scientific Officer |
• • – |
2016-04-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
975 |
3,609 |
|
- |
|
| Cox John |
EVP Pharmaceutical Oper & Tech |
• • – |
2016-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,444 |
39,045 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-04-01 |
4 |
AS |
$258.83 |
$126,050 |
D/D |
(487) |
60,434 |
|
- |
|
| Scangos George A |
Chief Executive Officer |
• • – |
2016-03-01 |
4 |
AS |
$261.37 |
$127,287 |
D/D |
(487) |
60,921 |
|
- |
|
2109 Records found
|
|
Page 19 of 85 |
|
|
0.53 (0.23%) 
